– Reuters
Truist Securities Maintains Buy on Roku, Lowers Price Target to $90
Truist Securities analyst Matthew Thornton maintains Roku (NASDAQ:ROKU) with a Buy and lowers the price target from $120 to $90.
Related Posts
Lineage Cell Therapeutics Q3 EPS $(0.04) Misses $(0.03) Estimate, Sales $3.00M Miss $3.90M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 20 percent increase over losses of $(0.05) per share
Gritstone’s Cancer Drug Shows Strong Tumor-Specific Responses In Various Settings
Gritstone bio Inc (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…
EXCLUSIVE: Expert Advice On How To Become Compliant Psychedelics Cultivator And Manufacturer
What can businesses and clients expect from psychedelic-assisted therapies (PAT)? What are state regulations looking like from a for-profit perspective and what does it take to provide safe, effective and compliant treatments?